The shares were sold at an average price of $9.57, for a total value of $ ... 29.10% of the stock is owned by insiders. Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs ...

February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the completion of the transaction, the director now owns 6,360 shares of the company ...

D-Wave shares are likely to remain on watchlists Tuesday after surging to a multi-year high as investors continued to pile ...

In his TAZR Trader he ripped D-Wave Quantum (QBTS) for a1,000% gain after adding it back in September. There’s been an incredible run in this stock in just the last five sessions, with it more ...

Therefore, the Zacks rating upgrade for D-WAVE QUANTUM basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

D-Wave Quantum's Q4 2024 results showed strong ... Hold rating remains due to but long-term outlook for profitability. The stock is down a few dollars since then, but there was a slight recovery ...

D-Wave Quantum (QBTS) has recently experienced a significant surge in its stock, rising over 100% in the past week, despite reporting a wider-than-expected earnings loss for its fourth quarter.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...